- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 211/60
Total number of patents in this class: 571
10-year publication summary
41
|
40
|
45
|
51
|
37
|
34
|
28
|
35
|
26
|
25
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
ChemoCentryx, Inc. | 386 |
35 |
Meiji Seika Pharma Co., Ltd. | 247 |
15 |
Corsair Pharma, Inc. | 37 |
13 |
Novartis AG | 10744 |
11 |
API Corporation | 225 |
11 |
Life Technologies Corporation | 3306 |
10 |
Biogen MA Inc. | 894 |
9 |
Omeros Corporation | 306 |
9 |
Bristol-myers Squibb Company | 4880 |
7 |
Kaneka Corporation | 4534 |
7 |
Global Blood Therapeutics, Inc. | 181 |
7 |
Helsinn Healthcare SA | 229 |
7 |
Xinfa Pharmaceutical Co., Ltd. | 22 |
7 |
Takeda Pharmaceutical Company Limited | 2708 |
6 |
Bnh Research Co.,Ltd. | 10 |
6 |
The Regents of the University of California | 19961 |
5 |
Araxes Pharma LLC | 92 |
5 |
Rottapharm Biotech S.r.l. | 43 |
5 |
West China Hospital, Sichuan University | 198 |
5 |
Renovel Innovations, Inc | 10 |
5 |
Other owners | 386 |